GSK to Acquire Nuvalent for $10.6 Billion, Boosting Oncology Pipeline with Late-Stage Lung Cancer Assets

summarizeSummary

GSK is acquiring Nuvalent for $10.6 billion, gaining late-stage oncology assets for lung cancer that are expected to significantly boost future sales and profits.

check_boxKey Events

• Acquisition of Nuvalent

  GSK will acquire Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on oncology, for an aggregate equity value of $10.6 billion.

• Strategic Oncology Assets

  The acquisition includes two late-stage, potential best-in-class ROS1 and ALK inhibitors (zidesamtinib and neladalkib) for non-small cell lung cancer, both currently under US FDA review for 2026 approvals.

• Financial Impact

  The deal is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029, with low single-digit percentage dilution to core EPS for 2026-2028.

• Market Premium

  The purchase price of $124 per share represents a 40% premium to Nuvalent's last closing price.

auto_awesomeAnalysis

This acquisition significantly strengthens GSK's oncology pipeline by adding three lung cancer assets, including two late-stage, potential best-in-class inhibitors currently under FDA review. The $10.6 billion deal, representing a substantial portion of GSK's market capitalization, is a major strategic move expected to drive sales and core operating profit growth from 2027, despite minor near-term EPS dilution. It positions GSK for accelerated entry and expansion in the lung cancer market.